SCHEMBL483878

SCHEMBL483878

CCOC(CN(C(=O)OC(C)(C)C)c1ccc(N2CCOCC2)c(F)c1)OCC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.45
USP30 Q70CQ3 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 2/20 0.41
ALOX15 P16050 2/20 0.40
MAPK1 P28482 2/20 0.40
RAB9A P51151 2/20 0.40
TP53 P04637 1/20 0.40
TSHR P16473 1/20 0.40
LDHA P00338 1/20 0.39
LDHB P07195 1/20 0.39
MAPT P10636 3/20 0.38
KDM4E B2RXH2 2/20 0.38
SLC6A9 P48067 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
GAA P10253 2/20 0.36
POLB P06746 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL484059 0.90 NPC1 (0.44) NPC1USP30SMN1; SMN2HPGDLMNA
SCHEMBL483892 0.90 NPC1 (0.47) NPC1SMN1; SMN2HPGDLMNAALDH1A1
SCHEMBL483968 0.87 NPC1 (0.44) NPC1SMN1; SMN2HPGDLMNAALDH1A1
SCHEMBL15627610 0.85 NPC1 (0.43) NPC1USP30SMN1; SMN2HPGDLMNA
SCHEMBL483627 0.85 NPC1 (0.43) NPC1USP30SMN1; SMN2HPGDLMNA
SCHEMBL483922 0.83 NPC1 (0.47) NPC1USP30SMN1; SMN2HPGDLMNA
SCHEMBL483902 0.82 NPC1 (0.47) NPC1SMN1; SMN2HPGDLMNAALDH1A1
SCHEMBL483943 0.82 MLYCD (0.48) NPC1USP30SMN1; SMN2HPGDLMNA
SCHEMBL483912 0.81 MAOB (0.45) NPC1USP30SMN1; SMN2HPGDLMNA
SCHEMBL483882 0.81 NPC1 (0.40) NPC1USP30SMN1; SMN2HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives DIPHARMA FRANCIS S.R.I. (IT) 2009-06-18 US claimed
EP-2072505-B1 A process for the preparation of oxazolidinone derivatives DIPHARMA FRANCIS SRL (IT) 2012-02-01 EP disclosed
EP-2072505-A2 A process for the preparation of oxazolidinone derivatives Dipharma Francis S.r.l. (IT) 2009-06-24 EP disclosed
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives DIPHARMA FRANCIS S.R.I. (IT) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives OXA1L, AAAS, MLYCD NPC1 4601/4885USP30 3430/4885SMN1; SMN2 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.